Hsbc Holdings PLC Reduces Stock Holdings in Zoetis Inc. $ZTS

Hsbc Holdings PLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 10.8% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 1,839,811 shares of the company’s stock after selling 223,359 shares during the period. Hsbc Holdings PLC owned approximately 0.45% of Zoetis worth $132,132,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Louisiana State Employees Retirement System acquired a new position in shares of Zoetis in the first quarter worth about $2,542,000. Wealthfront Advisers LLC grew its stake in Zoetis by 80.2% during the 2nd quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock valued at $5,469,000 after purchasing an additional 33,873 shares in the last quarter. Deutsche Bank AG grew its stake in Zoetis by 19.1% during the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock valued at $699,331,000 after purchasing an additional 891,921 shares in the last quarter. Pincus Capital Management LP purchased a new stake in Zoetis during the 4th quarter worth approximately $2,109,000. Finally, Diamond Hill Capital Management LLC Investment Advisor increased its holdings in Zoetis by 21.5% during the 2nd quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company’s stock worth $255,637,000 after purchasing an additional 629,974 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.2%

NYSE:ZTS opened at $77.29 on Wednesday. The company has a market cap of $31.94 billion, a PE ratio of 12.73, a P/E/G ratio of 1.80 and a beta of 0.74. The business’s 50 day moving average is $75.66 and its two-hundred day moving average is $96.47. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. Zoetis Inc. has a 52 week low of $71.00 and a 52 week high of $156.49.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business’s quarterly revenue was down .2% on a year-over-year basis. During the same period in the previous year, the business earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, analysts predict that Zoetis Inc. will post 6.2 EPS for the current year.

Analysts Set New Price Targets

ZTS has been the subject of several research analyst reports. Piper Sandler reduced their target price on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Zacks Research lowered shares of Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Barclays cut their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $107.43.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.